Brief: Ocugen Says OCU400 Remains On Track For 2026 BLA And MAA Approval Targets
10/04/2024 12:19
April 10 (Reuters) - Ocugen Inc OCGN.O :
* OCUGEN, INC. ANNOUNCES POSITIVE SCIENTIFIC ADVICE FROM THE
EUROPEAN MEDICINES AGENCY RELATED TO THE APPROVAL PATHWAY FOR
OCU400—MODIFIER GENE THERAPY FOR BROAD RETINITIS PIGMENTOSA
INDICATION
* OCUGEN INC: OCU400 REMAINS ON TRACK FOR 2026 BLA AND MAA
APPROVAL TARGETS
* OCUGEN INC: POSITIVE SCIENTIFIC ADVICE FROM EMA IS IN
ALIGNMENT
WITH U.S. FDA CLEARANCE OF IND AMENDMENT
Source text for Eikon: ID:nGNX5HmhNP
Further company coverage: OCGN.O
((Reuters.Briefs@thomsonreuters.com;))